Forte Biosciences CFO exercises RSUs, withholds shares

Riley Antony A reported disposition transactions in this Form 4 filing.

Rhea-AI Filing Summary

Riley Antony A reported disposition transactions in this Form 4 filing.

Forte Biosciences, Inc. chief financial officer Riley Antony A exercised 375 restricted stock units into an equal number of common shares on October 1, 2025. In connection with this vesting, 134 common shares were delivered at $14.52 per share to satisfy tax liability. Following these transactions, Antony directly holds 31,840 Forte Biosciences common shares and 1,875 RSUs remain outstanding under an award that vests one‑sixteenth on each quarterly vesting date, subject to continued service.

Insider Trade Summary

375 shares exercised/converted

Exercise 3 txns

Insider Riley Antony A

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	375	$0.00	$0.00
Exercise	Common Stock	375	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	134	$14.52	$2K

Holdings After Transaction: Restricted Stock Units — 1,875 contracts (Direct); Common Stock — 31,840 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
2. F2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

Key Figures

RSUs Exercised: 375 RSUs Shares Withheld for Taxes: 134 shares Tax Withholding Price: $14.52 per share +3 more

6 metrics

RSUs Exercised 375 RSUs Restricted stock units converted into common stock on October 1, 2025

Shares Withheld for Taxes 134 shares Common shares delivered to satisfy tax liability related to RSU vesting

Tax Withholding Price $14.52 per share Price applied to 134-share tax-withholding disposition

Remaining RSUs 1,875 RSUs RSUs still outstanding under the CFO’s equity incentive award

Post-Transaction Share Holding 31,840 shares Direct common stock holdings after the reported transactions

Quarterly Vesting Fraction 1/16 Portion of RSU award vesting on each Quarterly Vesting Date

Key Terms

Restricted Stock Units, Quarterly Vesting Date, Service Provider, 2021 Equity Incentive Plan

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Quarterly Vesting Date financial

"means January 1, April 1, July 1, and October 1 with respect to any calendar year"

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider through each vesting date"

2021 Equity Incentive Plan financial

"as defined in the 2021 Equity Incentive Plan through each applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Forte Biosciences (FBRX) disclose for its CFO on October 1, 2025?

Forte Biosciences reported its CFO Riley Antony A exercised 375 RSUs, converting them into common shares. On the same date, 134 shares were delivered at $14.52 per share to cover tax liability related to the vesting of this restricted stock unit award.

How many Forte Biosciences (FBRX) restricted stock units did the CFO exercise and how many remain?

The CFO exercised 375 restricted stock units into common stock. After this transaction, 1,875 RSUs from the award remain outstanding, continuing to vest in 1/16 increments on specified quarterly vesting dates, subject to ongoing service as a Service Provider.

How many Forte Biosciences (FBRX) shares does the CFO hold after the reported Form 4 transactions?

After the October 1, 2025 transactions, the CFO directly holds 31,840 common shares of Forte Biosciences. This post-transaction holding reflects the RSU conversion and the 134-share tax-withholding disposition reported in the insider filing.

At what price were Forte Biosciences (FBRX) shares delivered to satisfy the CFO’s tax liability?

134 Forte Biosciences common shares were delivered at $14.52 per share to satisfy tax liability. This disposition was reported under transaction code F, which covers payment of exercise price or taxes by delivering securities rather than cash.

What is the vesting schedule for the Forte Biosciences (FBRX) RSU award held by the CFO?

The RSU award vests one-sixteenth on each Quarterly Vesting Date, defined as January 1, April 1, July 1, and October 1 of each year, starting on or immediately following February 1, 2023, subject to the CFO’s continued status as a Service Provider.

How are Forte Biosciences (FBRX) RSUs structured for the CFO according to this filing?

Each RSU represents a contingent right to receive one share of common stock of Forte Biosciences. The award vests in equal quarterly installments, with each vested RSU converting into one share, creating potential future increases in the CFO’s common stock holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/02/2025 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Riley Antony A

(Last) (First) (Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BLDG 6

(Street)

DALLAS TX 75247

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M		375	A	$0(1)	31,974	D
Common Stock	10/01/2025		F		134	D	$14.52	31,840	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	10/01/2025		M			375	(2)	(2)	Common Stock	375	$0	1,875	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

	/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.